CRYO CELL INTERNATIONAL INC 8-K

What Happened

• Cryo-Cell International, Inc. (CCEL) filed an 8-K on May 8, 2026 reporting that on May 6, 2026 NYSE Regulation accepted the company’s compliance plan (originally submitted April 8, 2026).
• NYSE American has granted a plan period through September 9, 2027 during which Cryo-Cell’s common stock will remain listed and traded, subject to the company’s adherence to the plan and ongoing review. The company warned there is no assurance it will regain compliance by the deadline.

Key Details

• Compliance plan submitted: April 8, 2026; acceptance notice dated May 6, 2026; plan period ends: September 9, 2027.
• Common stock will continue trading on NYSE American during the plan period, conditional on compliance with the plan.
• If Cryo-Cell fails to regain compliance or make sufficient progress, NYSE American may initiate delisting proceedings.
• The company furnished a press release dated May 8, 2026 as Exhibit 99.1 to the 8-K.

Why It Matters

• For investors, this preserves CCEL’s current listing and trading liquidity for now, which is important for buying/selling and broader market access.
• The acceptance of a compliance plan is a temporary reprieve—not a resolution—so the risk of future delisting remains if the company does not meet NYSE American standards by Sept. 9, 2027.
• Shareholders should monitor the company’s progress updates and future SEC filings for developments that could affect liquidity, investor confidence, and share value.